Trial Profile
A Phase 1/2 Study of Nivolumab (BMS-936558) in Combination With Ipilimumab (BMS-734016) in Chinese Participants With Previously Treated Metastatic or Recurrent Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 01 Mar 2024 Status changed from active, no longer recruiting to completed.
- 26 Oct 2023 Planned End Date changed from 29 Sep 2023 to 8 Jan 2024.
- 26 Oct 2023 Planned primary completion date changed from 27 Oct 2022 to 8 Jan 2024.